Ignite Creation Date:
2024-05-06 @ 6:13 PM
Last Modification Date:
2024-10-26 @ 2:43 PM
Study NCT ID:
NCT05583383
Status:
RECRUITING
Last Update Posted:
2022-10-17
First Post:
2022-10-13
Brief Title:
A Study of the Advanced Adenocarcinoma of Stomach and Gastroesophageal Junction With CamrelizumabSOX Control CamrelizumabSOX Trastuzumab
Sponsor:
Henan Cancer Hospital
Organization:
Henan Cancer Hospital
Study Overview
Official Title:
A Phase II Clinical Study of the New Adjuvant Treatment of HER-2 Positive Resectable Locally Advanced Adenocarcinoma of Stomach and Gastroesophageal Junction With CamrelizumabSOX Control CamrelizumabSOX Trastuzumab
Status:
RECRUITING
Status Verified Date:
2022-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A Study of the Advanced Adenocarcinoma of Stomach and Gastroesophageal Junction With CamrelizumabSOX Control CamrelizumabSOX Trastuzumab
Detailed Description:
To observe the efficacy safety postoperative pathological remission rate and survival benefit of patients with HER-2 positive locally advanced adenocarcinoma of stomach and gastroesophageal junction treated with camrelizumabSOX combined with trastuzumab or not
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None